Hims & Hers is a direct-to-consumer telehealth platform connecting patients with licensed providers and fulfilling prescriptions through online pharmacies across sexual health, hair loss, weight loss, dermatology, and mental health. The majority of revenue is subscription-based and generated in the United States. The company is in active international expansion through acquisitions and organic entry into Europe and Canada.
Revenue grew 59% to $2.35B but subscriber growth decelerated 59% year-over-year, over 70% of US revenue is concentrated in compounded personalized formulations subject to FDA shortage-list risk, and the company is assuming up to $910M in deferred acquisition obligations payable within 18 months of a mid-2026 close.
Revenue compounded at roughly 64% over two years to $2.35B with improving revenue per subscriber, and the platform is demonstrating the ability to expand across gender and condition categories. If GLP-1 compounding regulations stabilize and Eucalyptus closes successfully, the combined entity would have meaningful scale across six international markets with a proven subscription monetization model.
Over 70% of US revenue now depends on personalized compounded formulations, predominantly GLP-1s, which face an existential regulatory risk if FDA removes the drug shortage designation for semaglutide or tirzepatide. Simultaneously, the company is taking on up to $910M in deferred and contingent obligations from the Eucalyptus acquisition payable within 18 months, and subscriber growth decelerated 59% in 2025, suggesting the core growth engine is maturing precisely when capital needs are peaking.
Management expects personalized offerings to increasingly drive US revenue growth. International expansion is expected to accelerate following the Eucalyptus acquisition expected to close mid-2026. No specific quantitative revenue or earnings guidance was provided in the excerpted sections.
Hims & Hers operates a vertically integrated telehealth platform combining provider network, EMR, and pharmacy fulfillment, which creates switching friction for subscribers on recurring plans. However, the company faces competition from large health systems, traditional pharma, and well-funded digital health peers, and its moat is largely brand and distribution rather than proprietary clinical IP. Regulatory barriers in compounding and telehealth prescribing can function as both a moat and a liability depending on enforcement direction.